Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Methylation & Proteomics-Based Detection of Bladder Cancer

Methylation & Proteomics-Based Detection of Bladder Cancer

226

Study never Launched

This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer. This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.
Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 09/09/2018

Thank you to everyone who made the 33rd EDRN Steering Committee Meeting a great success. The 34th EDRN Steering Committee Meeting is from March 18-20, 2019 in Nashville, TN. Details available in January, 2019.

Announcement